20 research outputs found
Fault isolation in overhead distribution networks: new developments in outdoor fault detectors
In recent years, the importance of power quality is rapidly growing. As a consequence, distributors are called to guarantee a reduced number and duration of supply interruptions by adopting new strategies in order to identify and isolate faults along distribution feeders. In the paper some recent results obtained in the development of outdoor fault detectors for overhead lines are reported. Furthermore many possible applications of the innovative current and voltage sensors to future active distribution networks with distributed generation have been identified
Comparison of the effects of cefuroxime axetil and cefaclor on the fecal flora in pediatric patients
Multicentric retrospective study of children affected by Wilson disease with hepatic presentation
J Pediatr Gastroenterol Nut
Persistence of elevated aminotransferases in Wilson's disease despite adequate therapy
Elevated aminotransferase activity can persist in patients with Wilson's disease despite adequate therap
Persistence of elevated aminotransferases in Wilson's disease despite adequate therapy
Elevated aminotransferase activity can persist in patients with Wilson's disease despite adequate therap
Serum transaminases in children with Wilson's disease
Objectives: The response of serum transaminase levels to penicillamine and zinc treatment in Wilson's disease is poorly understood. The aim of this multicenter retrospective study was to evaluate transaminase levels after penicillamine and zinc treatment in children with Wilson's disease.Patients and Methods: One hundred and nine patients with Wilson's disease (median age at diagnosis, 7.2 years; range, 1 to 18 years), treated for at least 12 months and observed in the last 20 years at 11 Paediatric Departments were studied. Clinical, laboratory and histologic features at diagnosis and initial treatment were recorded. Efficacy parameters were normalization of serum transaminase level and improved clinical and/or laboratory signs. One hundred and two patients had clinical or laboratory signs of liver disease.Results: Fifty-six of 87 patients (64%) given penicillamine normalized serum alanine aminotransferase (ALT) levels within a median of 17 months (range, 2 to 96 months). Of the 29 patients with persistent hyper-ALT, 17 (59%) switched to zinc; only four of these normalized ALT on zinc within a (50%) of the 22 patients given zinc alone normalized ALT within a median period of 6 months (range, 1 to 36 months). Of the 11 patients with persistent hyper-ALT, five switched to penicillamine. Three of the five normalized ALT within a median period of 6 months (range, 6 to 9 months). Overall, in penicillamine-treated and zinc-treated patients with persistent hypertransaminasemia, ALT decreased from a basal median of 236 IU/L (range, 54 to 640 IU/L) to a median of 78 (range, 46 to 960 IU/L) at the end of follow-up (P = 0.0245). Poor compliance was suspected in only 10% of cases. No predictive factor of persistent hypertransaminasemia was identified. Liver disease did not worsen in any patient during the study.Conclusions: Although the efficacy of penicillamine and zinc is well documented, it is notable that a subset of children with Wilson's disease-related liver disease (36%) had hypertransaminasemia despite appropriate treatment with penicillamine or zinc. (C) 2004 Lippincott Williams Wilkins
Serum Transaminases in Children with Wilson's Disease
OBJECTIVES: The response of serum transaminase levels to penicillamine and zinc treatment in Wilson's disease is poorly understood. The aim of this multicenter retrospective study was to evaluate transaminase levels after penicillamine and zinc treatment in children with Wilson's disease.
PATIENTS AND METHODS: One hundred and nine patients with Wilson's disease (median age at diagnosis, 7.2 years; range, 1 to 18 years), treated for at least 12 months and observed in the last 20 years at 11 Paediatric Departments were studied. Clinical, laboratory and histologic features at diagnosis and initial treatment were recorded. Efficacy parameters were normalization of serum transaminase level and improved clinical and/or laboratory signs. One hundred and two patients had clinical or laboratory signs of liver disease.
RESULTS: Fifty-six of 87 patients (64%) given penicillamine normalized serum alanine aminotransferase (ALT) levels within a median of 17 months (range, 2 to 96 months). Of the 29 patients with persistent hyper-ALT, 17 (59%) switched to zinc; only four of these normalized ALT on zinc within a median period of 38 months (range, 7 to 48 months). Eleven (50%) of the 22 patients given zinc alone normalized ALT within a median period of 6 months (range, 1 to 36 months). Of the 11 patients with persistent hyper-ALT, five switched to penicillamine. Three of the five normalized ALT within a median period of 6 months (range, 6 to 9 months). Overall, in penicillamine-treated and zinc-treated patients with persistent hypertransaminasemia, ALT decreased from a basal median of 236 IU/L (range, 54 to 640 IU/L) to a median of 78 (range, 46 to 960 IU/L) at the end of follow-up (P = 0.0245). Poor compliance was suspected in only 10% of cases. No predictive factor of persistent hypertransaminasemia was identified. Liver disease did not worsen in any patient during the study.
CONCLUSIONS: Although the efficacy of penicillamine and zinc is well documented, it is notable that a subset of children with Wilson's disease-related liver disease (36%) had hypertransaminasemia despite appropriate treatment with penicillamine or zinc
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
Fludarabine plus cytarabine (Ara-C) and idarubicin (FLAI) is an effective and
well-tolerated induction regimen for the treatment of acute myeloid
leukaemia (AML). This phase III trial compared the efficacy and toxicity of
FLAI versus idarubicin plus Ara-C and etoposide (ICE) in 112 newly
diagnosed AML patients <60 years. Fifty-seven patients received FLAI, as the
first induction–remission course, and 55 patients received ICE. Postinduction
treatment consisted of high-dose Ara-C (HDAC). After HDAC,
patients in complete remission (CR) received a second consolidation course
(mitoxantrone, etoposide, Ara-C) and autologous stem cell transplantation
(auto-SCT) or allogeneic (allo)-SCT, according to the age, disease risk and
donor availability. After a single induction course, CR rate was 74% in the
FLAI arm and 51% in the ICE arm (P ¼ 0Æ01), while death during induction
was 2% and 9% respectively. Both haematological (P ¼ 0Æ002) and nonhaematological
(P ¼ 0Æ0001) toxicities, especially gastrointestinal (i.e.
nausea, vomiting, mucositis and diarrhoea), were significantly lower in
FLAI arm. In both arms, relapses were more frequent in patients who were
not submitted to allo-SCT. After a median follow-up of 17 months, 30% and
38% of the patients are in continuous CR in FLAI and ICE arm respectively.
Our prospective randomised study confirmed the anti-leukaemic effect and
the low toxic profile of FLAI as induction treatment for newly diagnosed
AML patients